drugset / Trial / NCT03542955

Pulse Shortwave Therapy in Cervical Osteoarthritis

NCT03542955

Completed 180 enrolled BioElectronics Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The ActiPatch is an FDA cleared pain therapy device that uses pulsed shortwaves to interrupt pain signals at the nerve. 200 patients will be randomized and divided into an ActiPatch treatment group and comparison analgesic drug therapy group . Subjects will be assessed with the Neck Disability Index (NDI) at baseline and at four weeks and VAS scores will be recorded in order to determine the efficacy of the ActiPatch device compared to Etoricoxib. Cervical osteoarthritis causes chronic neck pain which could potentially be alleviated by the ActiPatch without the use of medication.

Timeline

Start
2018-05-01
Primary completion
2019-07-30
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoricoxib Small molecule 60 mg

Indications